ArticleParkinson's disease2012
Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease.
Article in Parkinson's disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- A Convergent Pathway for Stimulation-Induced Dyskinesia Following Deep Brain Stimulation.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- Inefficacy of Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease Patients with Levodopa-Induced Dyskinesias: Results from a Pilot Study.Biomedicines · 2025Article
- Neuroprotective effect of L-DOPA-induced interleukin-13 on striatonigral degeneration in cerebral ischemia.Cell death & disease · 2024Article
- Quantifying harmony between direct and indirect pathways in the basal ganglia: healthy and Parkinsonian states.Cognitive neurodynamics · 2024Article
- Break-up and recovery of harmony between direct and indirect pathways in the basal ganglia: Huntington's disease and treatment.Cognitive neurodynamics · 2024Article
- Enhanced Physicochemical Stability of the L-DOPA Extract ofMolecules (Basel, Switzerland) · 2023Article
- Toxin Induced Parkinsonism and Hospitalization Related Adverse Outcome Mitigation for Parkinson's Disease: A Comprehensive Review.Journal of clinical medicine · 2023Review
- A dynamical model for the basal ganglia-thalamo-cortical oscillatory activity and its implications in Parkinson's disease.Cognitive neurodynamics · 2021Article
- Management Challenges of Severe, Complex Dyskinesia. Data from a Large Cohort of Patients Treated with Levodopa-Carbidopa Intestinal Gel for Advanced Parkinson's Disease.Brain sciences · 2021Article
- Effects of bilateral subthalamic nucleus deep brain stimulation on motor symptoms in Parkinson's disease: a retrospective cohort study.Neural regeneration research · 2021Article
- Research advances on L-DOPA-induced dyskinesia: from animal models to human disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Review
- Subthalamic Single Cell and Oscillatory Neural Dynamics of a Dyskinetic Medicated Patient With Parkinson's Disease.Frontiers in neuroscience · 2020Article
- Chitosan-Coated Hydroxypropylmethyl Cellulose Microparticles of Levodopa (and Carbidopa): In Vitro and Rat Model Kinetic Characteristics.Current therapeutic research, clinical and experimental · 2020Article
- Anti-dyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model.IBRO reports · 2019Article
- Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.Neurotoxicity research · 2019Article
- Pathophysiology of dyskinesia and behavioral disorders in non-human primates: the role of serotonergic fibers.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson's disease.Therapeutics and clinical risk management · 2018Review
- Open Science Meets Stem Cells: A New Drug Discovery Approach for Neurodegenerative Disorders.Frontiers in neuroscience · 2018Review
- Motor Complications of Dopaminergic Medications in Parkinson's Disease.Seminars in neurology · 2017Review
- Acute hemichorea as unusual first multiple sclerosis presentation.Neurology. Clinical practice · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dyskinetic disorders are characterized by excess of motor activity that may interfere with normal movement control. In patients with Parkinson's disease, the chronic levodopa treatment induces dyskinetic movements known as levodopa-induced dyskinesias (LID). This paper analyzed the pathophysiology, clinical manifestations, pharmacological treatments, and surgical procedures to treat hyperkinetic disorders. Surgery is currently the only treatment available for Parkinson's disease that may improve both parkinsonian motor syndrome and LID. However, this paper shows the different mechanisms involved are not well understood.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.